Metrics to compare | SYNACT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYNACTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.1x | −2.6x | −0.2x | |
PEG Ratio | −0.53 | −0.05 | 0.00 | |
Price/Book | 5.8x | 0.9x | 2.6x | |
Price / LTM Sales | - | 146.6x | 2.8x | |
Upside (Analyst Target) | 166.9% | 657.1% | 62.1% | |
Fair Value Upside | Unlock | 48.9% | 9.5% | Unlock |
SynAct Pharma AB (publ), a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. The company has a strategic alliance with Hipolabor Farmacêutica LTDA for resomelagon in the treatment of dengue in Brazil. SynAct Pharma AB (publ) was founded in 2012 and is headquartered in Lund, Sweden.